ArticleNature communications2024

Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response.

Fara Brasó-Maristany et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.